Skip to main content
Contact Us
Sign Up
Subscriber Sign In
English
日本語
navigation
Search
What We Do
Vantage
News
Analysis
Policy & Pricing
Data Insights
Events
Medtech
Therapy Areas
About Vantage
Editorial team
Products & Services
Consensus Forecasts
Pharma
EvaluatePharma
EvaluatePharma Vision
Custom Solutions
How We Can Help You
Pharma and Biotech
Medtech
Financial Services
Management Consultancies
Service Providers
Client Success
Customer Testimonials
Thought Leadership
English
日本語
About Us
Media Centre
Press Releases
Media Coverage
Executive Team
Vision & History
Careers
Current Vacancies
Contact Us
Sign Up for Vantage
Subscriber Sign In
Search
Open configuration options
Search
Vantage
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Policy & Pricing
Policy & Regulation
Pricing
Data Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
About
Editorial team
XenoPort
May 25, 2016
Albireo finds a way to go public
May 24, 2016
Xenoport goes out with a whimper
September 16, 2015
Tolerability data blunt Xenoport’s Tecfidera
July 09, 2015
Event – XenoPort moves closer to its date with destiny
May 21, 2013
XenoPort sees little hope beyond the Horizant
March 14, 2013
Upcoming events: March 18 – 24
January 15, 2013
Event – XenoPort gets a second shot on goal with arbaclofen
October 10, 2012
Wockardt and Arena lead small-cap gainers through nine months
July 20, 2012
Key data readouts in the second half of 2012
June 08, 2012
New Horizant approval not enough to build XenoPort's value
August 18, 2011
Encouraging signs from quality of new drugs approved so far in 2011
Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device.
Find out more.
OK
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up
Latest Reports
December 17, 2019
Vantage 2020 Preview
July 31, 2019
Vantage Pharma, Biotech & Medtech Half-Year Review 2019
Editor's Picks
January 09, 2020
What makes a great year for takeovers?
January 07, 2020
Surprise! There’s a tumour in which Keytruda doesn’t work
December 19, 2019
Gene therapy clinical holds take centre stage
December 20, 2019
Plenty of choice remains for buyers of gene therapy
October 14, 2019
Uncovering biopharma’s hidden treasures
